LMAT vs MDT
LMAT: LeMaitre Vascular develops specialized medical devices and tissue-based solutions for vascular and cardiovascular surgery, targeting an aging population with peripheral vascular disease. MDT: Global medical device leader deploying pacemakers, defibrillators, spinal implants, surgical robotics, and diabetes management systems to alleviate pain, restore health, and extend life across 150+ countries.
Side-by-side fundamentals
| Metric | LMAT | MDT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $98.81 | $81.89 | |
| Market cap as of 2026-07-23 | $2.3B | $105.1B | |
| P/E as of 2026-07-23 | 36.84 | 21.88 | MDT lower |
| PEG as of 2026-07-23 | 1.00 | 2.90 | LMAT lower |
| Net margin as of 2026-07-23 | +24.4% | +13.2% | LMAT higher |
| Gross margin as of 2026-07-23 | +72.4% | +65.3% | LMAT higher |
| Operating margin as of 2026-07-23 | +28.5% | +17.8% | LMAT higher |
| ROE as of 2026-07-23 | +16.2% | +9.8% | LMAT higher |
| ROA as of 2026-07-23 | +10.3% | +5.2% | LMAT higher |
| Debt / equity as of 2026-07-23 | 0.42 | 0.57 | LMAT lower |
| Revenue growth (YoY) as of 2026-07-23 | +13.3% | +8.4% | LMAT higher |
| Revenue CAGR (3y) SEC XBRL | +15.6% | +5.2% | LMAT higher |
| Dividend yield as of 2026-07-23 | +1.0% | +3.5% | MDT higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-07-23 | 0.54 | 0.57 | |
| 1-year return as of 2026-07-22 close | +22.9% | -10.6% | LMAT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.